

INFORMATION DISCLOSURE CITATION			Docket No.: RLL-256US		Serial No.: 10/520,573	
			Applicants: MEHTA <i>et al.</i>			
			Filed: 1/7/2005		Group: Jason Nolan Art Unit 1626	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JN/	A1	2,490,714	12/6/1949	Searle	260	239	
/JN/	A2	3,176,019	3/30/1965	Campbell <i>et al.</i>	260	293.4	
/JN/	A3	5,001,160	3/19/1991	McPherson <i>et al.</i>	514	255	
/JN/	A4	5,164,402	11/17/1992	Brighty	514	300	
/JN/	A5	5,281,601	1/25/1994	Cross <i>et al.</i>	514	320	
/JN/	A6	5,397,800	3/14/1995	Alker <i>et al.</i>	514	413	
/JN/	A7	5,948,792	9/7/1999	Tsuchiya <i>et al.</i>	514	317	
/JN/	A8	6,130,232	10/10/2000	Mase <i>et al.</i>	514	318	
/JN/	A9	6,174,900	1/16/2001	Okada <i>et al.</i>	514	317	
/JN/	A10	6,313,312	11/6/2001	Banks <i>et al.</i>	548	452	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/>
/JN/	B1	CA 2155320	8/19/1993	Canada	C07D	211/68	<input type="checkbox"/>
/JN/	B2	EP 0 325 571	7/26/1989	EPO	C07C	215/54	<input type="checkbox"/>
/JN/	B3	EP 0 388 054	9/19/1990	EPO	C07D	207/08	<input type="checkbox"/>
/JN/	B4	EP 0 413 455	2/20/1991	EPO	C07D	401/04	<input type="checkbox"/>
/JN/	B5	EP 0 613 232	8/31/1994	EPO	H02M	3/335	<input type="checkbox"/>
/JN/	B6	EP 0 801 067	10/15/1997	EPO	C07D	453/02	<input type="checkbox"/>
/JN/	B7	EP 0 823 423	2/11/1998	EPO	C07D	211/46	<input type="checkbox"/>
/JN/	B8	EP 0 863 141	9/9/1998	EPO	C07D	401/06	<input type="checkbox"/>
/JN/	B9	GB 940,540	10/30/1963	UK	C07C		<input type="checkbox"/>
/JN/	B10	JP 135958/1994	5/17/1994	Japan	C07D	333/16	<input type="checkbox"/>
/JN/	B11	JP 92921/1994	4/5/1994	Japan	C07C	237/20	<input type="checkbox"/>

EXAMINER	/Jason Nolan/	DATE CONSIDERED	06/21/2007
----------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION					Docket No.: RLL-256US	Serial No.: 10/520,573
					Applicants: MEHTA et al.	
					Filed: 1/7/2005	Group: Jason Nolan Art Unit 1626

/JN/	B12	WO 91/09013	6/27/1991	PCT	C07D	207/08	
/JN/	B13	WO 93/16018	8/19/1993	PCT	C05F	17/02	
/JN/	B14	WO 93/16048	8/19/1993	PCT	C07D	211/26	
/JN/	B15	WO 96/33973	10/31/1996	PCT	C07D	211/46	
/JN/	B16	WO 97/45414	12/4/1997	PCT	C07D	211/58	
/JN/	B17	WO 98/05641	2/12/1998	PCT	C07D	211/46	
/JN/	B18	WO 98/29402	7/9/1998	PCT	C07D	311/20	
/JN/	B19	WO 98/53814	12/3/1998	PCT	A61K	31/395	
/JN/	B20	WO 01/42212	6/14/2001	PCT	C07D	211/48	
/JN/	B21	WO 01/42213	6/14/2001	PCT	C07D	211/58	
/JN/	B22	WO 01/90081	11/29/2001	PCT	C07D	241/08	
/JN/	B23	WO 02/00652	1/3/2002	PCT	C07D	453/02	
/JN/	B24	WO 02/04402	1/17/2002	PCT	C07C	219/10	
/JN/	B25	WO 02/51841	7/4/2002	PCT	C07D	453/02	
/JN/	B26	WO 02/06241	1/24/2002	PCT	C07D	223/16	
/JN/	B27	WO 02/53564	7/11/2002	PCT	C07D	453/02	
/JN/	B28	WO 04/004629	1/15/2004	PCT	A61K		
/JN/	B29	WO 04/005252	1/15/2004	PCT	C07D	209/52	
/JN/	B30	WO 04/014363	2/19/2004	PCT	A61K	31/40	
/JN/	B31	WO 04/014853	2/19/2004	PCT	C07D	209/02	
/JN/	B32	WO 04/018422	3/4/2004	PCT	C07D	209/52	
/JN/	B33	WO 04/052857	6/24/2004	PCT	C07D	209/52	
/JN/	B34	WO 04/056767	7/8/2004	PCT	C07D	207/14	
/JN/	B35	WO 04/056810	7/8/2004	PCT	C07D	405/12	
/JN/	B36	WO 04/056811	7/8/2004	PCT	C07D	405/12	
/JN/	B37	WO 04/089900	10/21/2004	PCT	C07D	209/52	

EXAMINER	/Jason Nolan/	DATE CONSIDERED	06/21/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-256US	Serial No.: 10/520,573
	Applicants: MEHTA et al.	
	Filed: 1/7/2005	Group: Jason Nolan Art Unit 1626

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/JN/	C1	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , <u>41</u> :691-721 (2001)
/JN/	C2	Cheng and Prusoff, "Relationship between the inhibition constant (K_1) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , <u>22</u> :3099-3108 (1973)
/JN/	C3	Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (5):215-219 (2001)
/JN/	C4	Brighty et al., "Synthesis of ($1\alpha,5\alpha,6\alpha$)-6-Amino-3-azabicyclo[3.1.0]hexane, a Novel Achiral Diamine", <i>Synlett</i> , 1097-1099 (1996)
/JN/	C5	Braish et al., "Construction of the ($1\alpha,5\alpha,6\alpha$)-6-Amino-3-azabicyclo[3.1.0]hexane Ring System", <i>Synlett</i> , 1100-1102 (1996)
/JN/	C6	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , <u>55</u> (Suppl. 5A):33-46 (2000)
/JN/	C7	Eglen et al., "Muscarinic receptor ligands and their therapeutic potential", <i>Current Opinion in Chemical Biology</i> , <u>3</u> :426-432 (1999)
/JN/	C8	Eglen et al., "Therapeutic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (8):409-414 (2001)
/JN/	C9	Felder et al., "Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , <u>43</u> (23):4333-4353 (2000)
/JN/	C10	Grover et al., "Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis", <i>Journal of Organic Chemistry</i> , <u>65</u> :6283-6287 (2000)
/JN/	C11	Shacklett and Smith, "The Preparation of Substituted Benzilic Acids", <i>Journal of the American Chemical Society</i> , <u>75</u> :2654-2657 (1953)
/JN/	C12	Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M ₃ Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , <u>45</u> :984-987 (2002)
/JN/	C13	Nkpa and Chedekel, "Mechanistic Studies on the Addition of Cysteine to 3,4-Dihydroxyphenylalanine", <i>Journal of Organic Chemistry</i> , <u>46</u> :213-215 (1981)
/JN/	C14	Kadin and Cannon, "Esters of N-Methyl-3-hydroxypiperidine Having Psychotomimetic Activity. II", <i>Journal of Organic Chemistry</i> , <u>27</u> :240-245 (1962)
/JN/	C15	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , <u>6</u> :142-193 (2001)
/JN/	C16	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , <u>64</u> (25):2351-2358 (1999)
/JN/	C17	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , <u>323</u> (2):411-416 (1986)

EXAMINER	/Jason Nolan/	DATE CONSIDERED	06/21/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE CITATION		Docket No.: RLL-256US	Serial No.: 10/520,573
		Applicants: MEHTA <i>et al.</i>	
		Filed: 1/7/2005	Group: Jason Nolan Art Unit 1626

/JN/	C18	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , 237:527-531 (1987)
/JN/	C19	Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , 2(3):268-282 2000
/JN/	C20	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)
/JN/	C21	Weinstock et al., "A General, One-Step Synthesis of α -keto Esters", <i>Synthetic Communications</i> , 11(12):943-946 (1981)
/JN/	C22	Vogel's textbook, "Practical Organic Chemistry" 1046-1047 (5th Ed.) 1989
/JN/	C23	"Design of prodrugs", ed. H. Bundgaard, Elsevier (1985)

EXAMINER	/Jason Nolan/	DATE CONSIDERED	06/21/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			